Polaryx Therapeutics, Inc. PLYX Accrued expenses and other liabilities

Accrued expenses and other liabilities at other companies

Midland States BancorpMSBI

$78.46M-28.4%

Hanmi FinancialHAFC

$74.58M-6.3%

DigitalBridge GroupDBRG

$615.37M-9.2%

ImaxIMAX

$88.14M-4.9%

CTO Realty GrowthCTO

$23.39M+17.0%

Century CommunitiesCCS

$276.77M-3.3%

Operating income-$2.0M+61.2%

Net income-$2.5M+49.6%

EPS (diluted)-$0.05+54.5%

Cash & equivalents$3.1M+1,132%

Total equity$2.5M-41.5%

Total assets$3.5M—

Operating cash flow-$2.1M-191%

Market cap$132.59M-86.9%

Return on equity-1,209.8%—

Current ratio3.5×—

Reported directly by Polaryx Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AccruedLiabilitiesAndOtherLiabilities.

The official record: Polaryx Therapeutics, Inc. ’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is Polaryx Therapeutics, Inc. 's accrued expenses and other liabilities?: Polaryx Therapeutics, Inc. (PLYX) reported accrued expenses and other liabilities of $21K in Q1 2026.